These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 11157020)

  • 1. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH; Mahmoud HH; Wiley JM; Woods GM; Leverger G; Camitta B; Hastings C; Blaney SM; Relling MV; Reaman GH
    J Clin Oncol; 2001 Feb; 19(3):697-704. PubMed ID: 11157020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
    Pui CH; Relling MV; Lascombes F; Harrison PL; Struxiano A; Mondesir JM; Ribeiro RC; Sandlund JT; Rivera GK; Evans WE; Mahmoud HH
    Leukemia; 1997 Nov; 11(11):1813-6. PubMed ID: 9369411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
    Rényi I; Bárdi E; Udvardi E; Kovács G; Bartyik K; Kajtár P; Masát P; Nagy K; Galántai I; Kiss C
    Pathol Oncol Res; 2007; 13(1):57-62. PubMed ID: 17387390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
    Pui CH
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):13-21. PubMed ID: 11694947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
    Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
    Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of impending tumor lysis with single-dose rasburicase.
    Lee AC; Li CH; So KT; Chan R
    Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
    Liu CY; Sims-McCallum RP; Schiffer CA
    Leuk Res; 2005 Apr; 29(4):463-5. PubMed ID: 15725482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
    Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European experience in the treatment of hyperuricemia.
    Patte C; Sakiroglu O; Sommelet D
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):9-12. PubMed ID: 11694946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
    Jeha S; Kantarjian H; Irwin D; Shen V; Shenoy S; Blaney S; Camitta B; Pui CH
    Leukemia; 2005 Jan; 19(1):34-8. PubMed ID: 15510203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
    Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
    Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.